ENOV

Enovis Corp

Add to Watchlist

Advanced Chart

28.110

-0.33(-1.160%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

29.180

Open

28.740

VWAP

28.26

Vol

1.15M

Mkt Cap

1.61B

Low

28.070

Amount

32.40M

EV/EBITDA(TTM)

9.74

Total Shares

54.85M

2.98B

EV/OCF(TTM)

15.83

P/S(TTM)

0.73

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

592.47M

+6.02%

0.810

+0.05%

592.99M

+5.71%

0.858

-12.44%

538.02M

+6.49%

0.653

-10.48%

Estimates Revision

The market is revising Downward the revenue expectations for Enovis Corporation (ENOV) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -23.13%.

Revenue Estimates for FY2025

Revise Downward

-0.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.09%

In Past 3 Month

Stock Price

Go Down

-23.13%

In Past 3 Month

10 Analyst Rating

87.37% Upside

Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 52.67 USD with a low forecast of 26.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

87.37% Upside

Current: 28.110

Low

26.00

Averages

52.67

High

75.00

87.37% Upside

Current: 28.110

Low

26.00

Averages

52.67

High

75.00

Canaccord

Buy

downgrade

$70 -> $58

2025-08-08

New

Reason

Canaccord

Price Target

$70 -> $58

2025-08-08

New

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Enovis to $58 from $70 and keeps a Buy rating on the shares. The firm said they posted a solid Q2 beat and noted the company maintained expectations to be FCF positive for the FY25 while CEO Damien McDonald outlined a vision focused on margin expansion, cash flow improvement, and disciplined execution through the EGX operating system.

UBS

Buy

downgrade

$65 -> $57

2025-08-08

New

Reason

UBS

Price Target

$65 -> $57

2025-08-08

New

downgrade

Buy

Reason

UBS lowered the firm's price target on Enovis to $57 from $65 and keeps a Buy rating on the shares.

Jehoshaphat Research

Strong Sell

initiated

2025-07-17

Reason

Jehoshaphat Research

Price Target

2025-07-17

initiated

Strong Sell

Reason

Jehoshaphat Research announced a new short position in Enovis. In a note to investors, the firm says it believes Enovis shareholders own a growth story "that's largely a figment of accountants' imaginations." The firm is short this stock because "we think its key numbers are largely fake, its real earnings power is far lower, and because it has gotten by for many years on a plethora of accounting and language games that simply won't work if the company is too debt-laden to do more large, frequent deals." Reference Link

Canaccord

Buy

downgrade

$75 -> $70

2025-05-14

Reason

Canaccord

Price Target

$75 -> $70

2025-05-14

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Enovis to $70 from $75 and keeps a Buy rating on the shares. The firm updated its model following Q1 results and the release of its 10Q.Canaccord lowered the price target by applying the same EV/Sales multiple in their last valuation update. While the comp group valuation average is slightly higher and their 2026 revenue estimate has risen, they impose a larger discount to the comp group.

JMP

Citizens

Outperform

maintain

$62 -> $55

2025-05-09

Reason

JMP

Citizens

Price Target

$62 -> $55

2025-05-09

maintain

Outperform

Reason

Citizens JMP lowered the firm's price target on Enovis to $55 from $62 and keeps an Outperform rating on the shares. Consolidated Q1 results in sales and adjusted EBITDA nearly matched consensus, and updated guidance for 2025 reflects the positive impacts of foreign exchange on the top-line range and the negative impact of tariffs on EPS and adjusted EBITDA, the firm says. The stock's valuation does not fully capture the benefits and potential upside of the complete integration of the Lima acquisition, Citizens argues.

Needham

Mike Matson

Strong Buy

Reiterates

$64

2025-04-09

Reason

Needham

Mike Matson

Price Target

$64

2025-04-09

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Enovis Corp (ENOV.N) is 8.95, compared to its 5-year average forward P/E of 21.32. For a more detailed relative valuation and DCF analysis to assess Enovis Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

21.32

Current PE

8.95

Overvalued PE

30.39

Undervalued PE

12.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.79

Current EV/EBITDA

7.32

Overvalued EV/EBITDA

18.48

Undervalued EV/EBITDA

7.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.62

Current PS

0.70

Overvalued PS

2.32

Undervalued PS

0.93